Mitralign is to outline data for its Trialign tricuspid repair system at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA). Rebecca Hahn will give presentation “early feasibility of a percutaneous tricuspid valve annuloplasty system for symptomatic chronic functional tricuspid regurgitation: 30-day results from the SCOUT trial” on 1 November at 8.29am. SCOUT I is a US multicentre easy feasibility study.
A press release reports that additionally, the company will host a sponsored symposium—Trialign: the new era of tricuspid repair—on 30 October from 11.30am to 12.30pm. The faculty include Martin Leon, Rebecca T Hahn, Azeem Latib, Scott Lim, Gorav Ailawadi, Charles Davidson, Christopher Meduri, and Joachim Schofer.
“We are excited to present data from the first clinical investigation in the United States on transcatheter tricuspid therapy. The 30 Day SCOUT I data establishes Trialign as one of the most promising solutions for patients with tricuspid disease,” says Rick Geoffrion, chief executive officer of Mitralign.